▟ Vinebot intrinsic value, daily

← back

HSIC Henry Schein

healthcare · valued with opus low conviction · deep-dived 2026-10-29

SELL
Intrinsic value$26.20
Price (at call)$84.96
Margin of safety -69.2%
vs market (rating basis) -31.2%

Scale distributor whose price already assumes a margin recovery it hasn't delivered yet; still looks expensive.

The story

Henry Schein is the largest dental and office-based medical distributor in North America and Europe. Its moat is scale, route density and practice-management software lock-in, but it earns thin margins and competes with Patterson, Benco and direct-to-practitioner channels. It is a mature business growing in the low single digits. Margins have been stuck near 5% since the 2023 cyberattack and pricing deflation, and management, with KKR as a backer, is running a cost and value-creation program to move them back toward pre-2022 levels.

TTM revenue of 13.60B is up about 3% on FY 13.18B, so year-1 growth rises to 3.5%. The baseline's -83% gap is far beyond any plausible mispricing for a heavily covered name, so I revisited margin and reinvestment. Target margin moves from 5.8% to 6.5%: that is the 2019-2021 GAAP level, the cost program is underway, and reported margins carry acquisition amortization of about 1.5 points. Sales-to-capital moves from 2.1 to 2.5 (a 19% move) because growth is mostly organic and capex-light; capex of 0.19B is below D&A of 0.30B. Beta moves down slightly to 0.95, close to the industry anchor.

Value drivers

Revenue growth (Y1)3.5%
Terminal growth2.5%
Forecast horizon7y
Target operating margin6.5%
Years to target margin6
Sales-to-capital2.50
Beta0.95
Failure probability2.0%
Cost of capital (WACC)8.6%
Terminal WACC8.8%

Valuation bridge

PV of explicit FCFF2.66B
PV of terminal value5.46B
Equity value2.98B
÷ shares → per share$26.20

Projected free cash flow to the firm

YrRevenueGrowthMarginNOPATReinvestFCFFPV
1 14.08B 3.5% 5.5% 586.05M 190.43M 395.62M 364.33M
2 14.55B 3.3% 5.7% 628.87M 187.71M 441.17M 374.15M
3 15.01B 3.2% 5.9% 672.82M 184.27M 488.55M 381.57M
4 15.46B 3.0% 6.1% 717.75M 180.10M 537.66M 386.72M
5 15.90B 2.8% 6.3% 763.54M 175.19M 588.35M 389.71M
6 16.32B 2.7% 6.5% 810.04M 169.56M 640.48M 390.69M
7 16.73B 2.5% 6.5% 830.29M 163.20M 667.09M 374.74M

Key risks

  • Margin recovery stalls because of glove and PPE deflation, mix shift to lower-margin generics, or competitive price pressure from Benco and Amazon Business
  • Dental procedure volumes soften in a consumer slowdown, hitting both consumables and equipment
  • Leverage (2.95B net debt) and serial bolt-on M&A reduce reinvestment efficiency and add integration or impairment risk

Catalysts

  • Delivery on the value-creation plan's non-GAAP margin targets and the high-growth/high-margin segment mix (specialty, technology, own brands)
  • Activist or KKR-driven portfolio actions such as divesting medical or monetizing the software segment

History

DatePriceIntrinsicMoSRating
2026-10-29$84.96 $26.20 -69.2% SELL
2026-09-09$88.86 $17.91 -79.8% SELL
2026-07-20$87.82 $20.95 -76.1% SELL
2026-06-23$80.10 $34.75 -56.6% HOLD